This article is more than 5 years old. Information may no longer be current.

PRN Therapeutics releases supplement for diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PRN Therapeutics announced the launch of Nuretin, a supplement formulated to manage high blood sugar levels that damage the retinal blood vessels.

Nuretin is a purified triglyceride form omega-3 that provides 1,200 mg of EPA and DHA in a 1:5 ratio and is expected to reduce the risk of diabetic retinopathy as well as slow the progression of the disease, according to a press release from PRN Therapeutics.

While Nuretin does not require a prescription, the “medical food” is available only with a doctor’s recommendation and is delivered directly by PRN Therapeutics, according to the company.

"We are excited to bring this much-needed therapeutic solution to the ophthalmic and optometric communities,” PRN Therapeutics CEO Ken Krieg said in the release. “The launch of Nuretin comes at a perfect time for the immense population of aging Baby Boomers who are being diagnosed with diabetes. Nuretin will provide an essential therapeutic tool for eye care professionals and physicians seeking to provide intervention to retinopathy among their diabetic patients."